Dr. Reddy’s (NYSE: RDY) plans Feb. 9, 2026 Mumbai investor meet

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its schedule for an upcoming investor interaction. The company’s management plans to participate in a Nuvama-organized investor conference in Mumbai on 9 February 2026, holding in-person group meetings from 09:00 to 17:00 IST. The company notes that this schedule may change if required by either the investors or the company.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

February, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated February 2, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: February 2, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

February 2, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings

This is to inform that the Company’s management will be participating in the following investor conference with single institution(s)/ investor groups:

Date	Organized by	Location	Meeting mode	Nature of meet	Timing
09.02.2026	Nuvama	Mumbai	In – Person	Group Meet	09:00 - 17:00 IST

Please note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.

This is for your information.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

FAQ

What did Dr. Reddy’s Laboratories (RDY) announce in this Form 6-K?

Dr. Reddy’s Laboratories announced management participation in an investor conference on 9 February 2026 in Mumbai. The meetings, organized by Nuvama, will be in-person group sessions scheduled between 09:00 and 17:00 IST, with timing subject to possible changes.

When and where will Dr. Reddy’s (RDY) investor meetings take place?

The investor meetings are scheduled for 9 February 2026 in Mumbai, India. They will occur at a Nuvama-organized conference, with group meetings planned from 09:00 to 17:00 IST, although the schedule may change if needed by investors or the company.

What is the format of Dr. Reddy’s (RDY) upcoming investor interaction?

Dr. Reddy’s management will hold in-person group meetings with analysts and institutional investors. These sessions are part of a Nuvama investor conference in Mumbai on 9 February 2026 and are planned to run throughout the day from 09:00 to 17:00 IST.

Who is organizing the February 9, 2026 Dr. Reddy’s (RDY) investor conference?

The investor conference featuring Dr. Reddy’s management is being organized by Nuvama. It will be held in Mumbai on 9 February 2026 and will include in-person group meetings with analysts and institutional investors over the course of the day.

Can the schedule of Dr. Reddy’s (RDY) February 2026 investor meetings change?

Yes, the company states that the meeting schedule is subject to change. Any exigencies affecting either investors or Dr. Reddy’s could lead to timing or schedule adjustments for the 9 February 2026 in-person group meetings in Mumbai.

Which stock exchanges were informed about Dr. Reddy’s (RDY) investor meetings?

The company informed the National Stock Exchange of India, BSE Limited, the New York Stock Exchange, and NSE IFSC Ltd. The intimation relates to management’s planned participation in a Nuvama investor conference in Mumbai on 9 February 2026.